Nuvation Bio

During #LungCancerAwarenessMonth, we are raising awareness about #ROS1 positive #NSCLC. Despite advances, new treatment options are urgently needed. At Nuvation Bio, we are passionate about changing the reality for patients and making a positive difference for them. #LCAM #lungcancer #oncology

Jean-Yves Maziere, MD, MS, Vice President of Pharmacovigilance, recently joined Nuvation. With oncology as the “center of gravity” for Jean-Yves in a long career focused on clinical, pharmacovigilance, and data science, he is excited to lead a global team of talented professionals during a critical part of our history as we evolve towards a commercial stage company. Learn more about our team’s impact: https://bit.ly/3YZuV44 #NUVBeginnings #oncology #cancer

Don’t miss Nuvation Bio’s presentation at the Jefferies London Healthcare Conference next Tuesday, where David Hung, M.D., our Founder, President, and CEO, will highlight plans for our lead #ROS1 inhibitor for #NSCLC, and progress across the rest of our #oncology pipeline. Learn more here: https://lnkd.in/eEwADBvE

Today we reported third quarter 2024 financial results and provided a business update. See more: https://bit.ly/48LyUEP #oncology #cancer #biotech?

As we launch wellness month here at Nuvation Bio, we believe it’s important to support our colleagues’ wellbeing, which is why we are excited for our 2nd Annual NUV on the Move initiative! This year we are proud to partner with The Leukemia & Lymphoma Society via Charity Miles to support a mission that’s close to our hearts. Learn about more ways our team is making an impact: https://shorturl.at/hkOFl

Please join us in welcoming Philippe Sauvage as our new Chief Financial Officer! Philippe brings over 20 years of global finance, operations, and commercialization experience across leading #healthcare and #biopharma companies that have made a difference for patients. He will be integral as we advance our mission to tackle some of the greatest unmet needs in #oncology. Read the announcement: https://lnkd.in/e3Q8f7pc

Today, on #WorldCancerResearchDay, we stand united in our mission to advance new possibilities in #cancer research and treatment. At Nuvation Bio, we are dedicated to developing our pipeline programs in #solidtumors – taletrectinib, safusidenib, NUV-1511, and NUV-868 – to change the lives of people with difficult-to-treat cancers. Learn more: https://rb.gy/kdfarb

Our team recently participated in a back-to-school backpack drive with Family Giving Tree. We were proud to come together to help give children the supplies they need to start the school year off right! Learn more about the great work Family Giving Tree is doing: https://lnkd.in/g-JdFJA

Today at #ESMO24, we shared pooled data from our pivotal studies, TRUST-I and TRUST-II, showcasing the potential for our #ROS1 inhibitor in #NSCLC. We look forward to our planned NDA submission in the fourth quarter of 2024 based on these data. Learn more: https://bit.ly/3Xu0G3o

Don’t miss Nuvation’s presentation at the Cantor Fitzgerald Global Healthcare Conference next Thursday, where management will highlight exciting data updates and next steps for our lead #ROS1 inhibitor for #NSCLC, and progress across the rest of our #oncology pipeline. Get details here: https://lnkd.in/eXdAcGDE